top of page
Browse by category
Search
TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in patients with acquired hypothalamic obesity
Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a...
Neurons that control the amount of MC4R affect how much the protein guards against obesity
Mutations in a gene called OTP cause obesity by controlling the output of another gene already targeted by an anti-obesity drug, a study...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
EMA grants Orphan Drug Designation for Setmelanotide for treatment of acquired hypothalamic obesity
The European Medicines Agency (EMA) has issued a positive opinion on the Rhythm Pharmaceuticals’ orphan drug designation request for...
Browse by tag
bottom of page